KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral therapies for rare diseases. Its main product is sebetralstat, a novel oral on-demand treatment for hereditary angioedema (HAE). HAE is a rare genetic condition characterized by recurrent swelling episodes. Additionally, KalVista has an oral Factor XIIa inhibitor program, which targets the same pathway to potentially prevent HAE attacks. The company's pipeline is centered on addressing unmet needs in HAE by providing convenient oral alternatives to injectable therapies. As of June 11, 2026, KalVista was taken private and operates as a subsidiary of Chiesi Farmaceutici S.p.A.

KalVista Pharmaceuticals was listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol KALV. The company traded in US dollars (USD). However, as of June 11, 2026, KalVista was taken private and is no longer publicly traded. It now operates as a subsidiary of Chiesi Farmaceutici S.p.A., an Italian pharmaceutical company. The delisting followed the acquisition, and the stock is no longer available on any exchange.

KalVista Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes to develop therapies and diagnostics. KalVista focuses on rare diseases, particularly hereditary angioedema (HAE), by developing oral small-molecule drugs. This places it in the therapeutic area of rare disease biotech, distinct from larger pharmaceutical companies that may have broader portfolios. The company's research and development efforts are centered on oral formulations to improve patient convenience and adherence.

KalVista Pharmaceuticals is headquartered in Framingham, Massachusetts, United States. The company develops therapies for global markets, with a focus on rare diseases such as hereditary angioedema (HAE). Its lead product, sebetralstat, is intended for on-demand treatment of HAE attacks and is designed for worldwide distribution. As a subsidiary of Chiesi Farmaceutici S.p.A., KalVista may leverage Chiesi's international infrastructure to reach patients in multiple regions. The company's research and clinical trials have involved sites in various countries, reflecting its global ambitions.

KalVista Pharmaceuticals is a biopharmaceutical company that generates revenue by developing and commercializing oral therapies for rare diseases. Its primary focus is on hereditary angioedema (HAE), with sebetralstat as its lead product candidate for on-demand treatment. The company also has an oral Factor XIIa inhibitor program for potential prophylactic use. Revenue would come from sales of approved drugs, but as of its takeover in June 2026, sebetralstat had not yet been commercialized. Following the acquisition by Chiesi Farmaceutici S.p.A., KalVista's operations are now part of a larger entity, and its pipeline may be advanced under Chiesi's resources. The company's model relies on successful clinical development, regulatory approval, and market access for its oral HAE therapies.